289 related articles for article (PubMed ID: 28970500)
1. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
2. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene.
Li S; Xu Z; Guo J; Zheng J; Sun X; Yu J
J Cell Mol Med; 2020 Dec; 24(24):14549-14560. PubMed ID: 33164339
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
6. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
7. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
[TBL] [Abstract][Full Text] [Related]
8. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
9. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma.
Peng HY; Cheng YC; Hsu YM; Wu GH; Kuo CC; Liou JP; Chang JY; Jin SL; Shiah SG
PLoS One; 2016; 11(7):e0158440. PubMed ID: 27367272
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
11. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
13. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
14. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
18. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
19. FXR induces SOCS3 and suppresses hepatocellular carcinoma.
Guo F; Xu Z; Zhang Y; Jiang P; Huang G; Chen S; Lyu X; Zheng P; Zhao X; Zeng Y; Wang S; He F
Oncotarget; 2015 Oct; 6(33):34606-16. PubMed ID: 26416445
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
